Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study [0.03%]
仑伐替尼联合经动脉化疗栓塞和PD-1抑制剂作为不可切除的中晚期肝细胞癌新辅助/转化治疗的II期临床研究及探索性生物标志物研究
Xiaoyun Zhang,Haozheng Cai,Wei Peng et al.
Xiaoyun Zhang et al.
Conversion therapy remains an uncommon strategy for managing unresectable hepatocellular carcinoma (uHCC) due to limited evidence supporting its efficacy. To address this gap, we initiated a prospective phase 2 multicenter trial (NCT0499785...
Multiomics Mendelian randomization identifies serpin family G member 1 as a chronic obstructive pulmonary disease modulator [0.03%]
多组学孟德尔随机化鉴定出蛋白酶抑制剂家族G成员1是慢性阻塞性肺疾病的调节因子
Erkang Yi,Jieda Cui,Hairong Wang et al.
Erkang Yi et al.
Chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide, lacks effective disease-modifying therapies, partly because of complex gene-environment interactions and extensive missing heritability. Here, we appl...
May Bakr,Mohamed Salama
May Bakr
Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma [0.03%]
糖酵解异质性驱动胰腺导管腺癌代谢靶向治疗
Ugo Chianese,Chiara Papulino,Gerardo Saggese et al.
Ugo Chianese et al.
Pancreatic ductal adenocarcinoma is traditionally characterized as a glycolytic tumor. However, the extent and clinical relevance of its metabolic heterogeneity remain poorly understood. In this study, we investigated whether glycolytic act...
Correction: Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients [0.03%]
纠正：循环肿瘤DNA可优化有限期小细胞肺癌患者的免疫巩固治疗
Yin Yang,Yuqi Wu,Jingjing Zhao et al.
Yin Yang et al.
Diabetes and its complications: molecular mechanisms, prevention and treatment [0.03%]
糖尿病及其并发症的分子机制、预防和治疗措施
Lijun Zhao,Jiamin Yuan,Qing Yang et al.
Lijun Zhao et al.
Diabetic complications represent a formidable clinical challenge characterized by hyperglycemia-induced multiorgan dysfunction and dysregulated intercellular signaling networks. Advances in spatial multiomics and single-cell transcriptomic ...
Astrocytic noncanonical WNT5B signaling modulates extracellular matrix remodeling and neuropathology in Huntington's disease [0.03%]
astrocyte非经典WNT5B信号通路调节亨廷顿病中的细胞外基质重塑及神经病理学变化
Phuong Thi Thanh Nguyen,Ali Yousefian-Jazi,Seung Jae Hyeon et al.
Phuong Thi Thanh Nguyen et al.
Huntington's disease (HD) is a fatal neurodegenerative disorder characterized by a triad of behavioral symptoms: involuntary movement, emotional change, and cognitive dysfunction. Although alterations in WNT signaling have been reported in ...
A microbiota-dependent bile acid reprograms alveolar macrophages to control lung inflammation [0.03%]
一种依赖微生物群的胆汁酸重新编程肺泡巨噬细胞以控制肺部炎症
Magdalena Wolska,Pilar Rodríguez-Viso,Anna Świątkowska et al.
Magdalena Wolska et al.
Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis [0.03%]
代谢功能紊乱相关脂肪性肝病通过巨噬细胞迁移抑制因子-CD44轴加速胰腺癌的进展和转移
Qian Yu,Hui Song,Xiao-Ya Shi et al.
Qian Yu et al.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, particularly in the presence of liver metastases. The mechanisms by which metabolic dysfunction-associated steatotic liver disease (MASLD), for...
Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations [0.03%]
胰腺癌中的垂直RAS通路抑制驱动了可药物利用的线粒体改变
Philipp Hafner,Steffen J Keller,Xun Chen et al.
Philipp Hafner et al.
Oncogenic KRAS mutations drive metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC). Src-homology 2 domain-containing phosphatase 2 (SHP2) is essential for full KRAS activity, and promising dual SHP2/mitogen-activated protein ...